NORD's
Washington Office
 Check here to read about events on Capitol Hill, funding for rare-disease research, and other topics of interest from NORD's office in Washington, DC.
|
|
|
Transcript of Social Security Commissioner Michael Astrue's remarks.Read the transcript.
Summit 2009 Power Point Presentations
Improving Treatment for Rare Diseases
Sol J. Barer, PhD
Chairman and CEO, Celgene |
|
Driving Innovation - FDA's Critical Path
Initiative
Rachel E. Behrman
MD, MPH
Associate Commissioner
for Clinical Programs
Food and Drug
Administration
|
|
A New Public-Private Partnership Model
for Rare and Neglected Disease Therapeutics
Francis S. Collins MD,PhD
|
|
|
|
|
|
Drug Approval Standard: Application to
Rare Diseases
John K. Jenkins, MD
Director, Office of New
Drugs
FDA Center for Drug
Evaluation and Research
|
|
Accelerating Innovation for Rare Diseases
Emil D. Kakkis
MD, PhD
President and Founder,
Kakkis EveryLife Foundation
Former Chief Medical
Officer, BioMarin Pharmaceutical Inc.
|
|
Challenges Faced by Industry
David Meeker, MD
Executive Vice President,
Therapeutics, Biosurgery and Transplant
Genzyme
|
| |
|
|
|
|
Balancing Safety and Access
Daniel G. Schultz, MD
Director, Center for
Devices and Radiological Health
Food and Drug
Administration
|
|
Proposal to Accelerate Development of
Treatments for Rare Diseases
Janet Woodcock, MD
Director, FDA Center for Drug Evaluation
and Research
|
|
CBER's Role in Development of Products
for Rare Diseases
Robert A.Yetter PhD
Associate Director for
Review Management
FDA Center for
Biologics Evaluation and Research
|
|
